Document Detail

Safety of nevirapine in pregnancy.
MedLine Citation:
PMID:  17305934     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Nevirapine has been widely used in pregnancy for its efficacy, low pill burden, bioavailability and rapid transplacental transfer. Concern about nevirapine toxicity during pregnancy has emerged over recent years. OBJECTIVES: The aims of the study were to document the frequency of cutaneous and hepatic toxicity secondary to nevirapine use during pregnancy and to compare rates in women starting nevirapine during the current pregnancy with those in women who had commenced nevirapine prior to the current pregnancy. DESIGN: This was a retrospective, comparative, five-centre study carried out in London, UK, in 1997-2003. METHODS: All HIV-1-infected women who received nevirapine as part of combination antiretroviral therapy (ART) during pregnancy were included in the study. Data on demographics, HIV infection risk, Centers for Disease Control and Prevention (CDC) status, surrogate markers at initiation of therapy, other medications hepatitis B and C virus coinfection and clinical data relating to potential toxicity were collated and analysed. RESULTS: Fifteen of 235 eligible women (6.4%) developed rash and eight (3.4%) developed hepatotoxicity, including four with coexistent rash, giving a combined incidence of 19 potential cases of nevirapine toxicity during pregnancy (8.1%). Alternative causes of rash/hepatotoxicity were suspected in seven cases and only 10 mothers (5.8%) discontinued nevirapine. Of the 170 women who commenced nevirapine during this pregnancy, 13 (7.6%) developed rash and eight (4.7%) hepatotoxicity, a combined incidence of 10%. Only two of 65 women with nevirapine exposure prior to this pregnancy developed rash (3.1%). CONCLUSIONS: Nevirapine-containing ART was well tolerated in this cohort of pregnant women. Although pregnancy did not appear to increase the risk of nevirapine-associated toxicity compared to published adult data, CD(4) count may be less predictive of toxicity in pregnancy.
U Natarajan; A Pym; C McDonald; P Velisetty; S G Edwards; P Hay; J Welch; A de Ruiter; G P Taylor; J Anderson
Related Documents :
12648834 - Murine model of pregnancy-associated listeria monocytogenes infection.
8286074 - Multiple sexual partners and mother-to-child transmission of hiv-1.
8018614 - Fetal immunological and haematological changes in intrauterine infection.
20503234 - Value of prenatal ultrasound and magnetic resonance imaging in assessment of congenital...
9591354 - Estimating intruder-related firearm retrievals in u.s. households, 1994.
11844314 - Anchorage in the developing placenta: an overlooked determinant of pregnancy outcome?
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Multicenter Study    
Journal Detail:
Title:  HIV medicine     Volume:  8     ISSN:  1464-2662     ISO Abbreviation:  HIV Med.     Publication Date:  2007 Jan 
Date Detail:
Created Date:  2007-02-19     Completed Date:  2007-11-02     Revised Date:  2009-11-19    
Medline Journal Info:
Nlm Unique ID:  100897392     Medline TA:  HIV Med     Country:  England    
Other Details:
Languages:  eng     Pagination:  64-9     Citation Subset:  IM    
Department of Genitourinary Medicine, Guy's and St Thomas' NHS Foundation Trust, London, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anti-HIV Agents / adverse effects*
Drug Therapy, Combination
Drug-Induced Liver Injury
Exanthema / chemically induced
HIV Infections / drug therapy*
Nevirapine / adverse effects*
Pregnancy Complications / chemically induced*
Pregnancy Complications, Infectious / drug therapy*
Retrospective Studies
Reg. No./Substance:
0/Anti-HIV Agents; 129618-40-2/Nevirapine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Treatment outcomes amongst previously antiretroviral-naïve HIV-infected patients starting lopinavir...
Next Document:  Vanishing bile duct syndrome in a patient with advanced AIDS.